Related Experiment Video
Updated: Jan 26, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of
Francis W Hunter1, Jules B L Devaux2, Fanying Meng2
1Auckland Cancer Society Research Centre, School of Medical Sciences, Faculty of Medical and Health Sciences (F.W.H., C.R.H., A.K., I.S., W.R.W.), Maurice Wilkins Centre for Molecular Biodiscovery (F.W.H., A.J.R.H., C.G.P., W.R.W.), School of Biological Sciences, Faculty of Science (J.B.L.D., A.J.R.H.), and Department of Molecular Medicine and Pathology, School of Medical Sciences, Faculty of Medical and Health Sciences (P.T., P.M.K., C.G.P., S.K.B.), University of Auckland, Auckland, New Zealand; Threshold Pharmaceuticals, South San Francisco, California (F.M., C.P.H.); Princess Margaret Genomics Centre (T.W.K.) and Princess Margaret Cancer Centre (S.M., Z.S., B.G.W.), University Health Network, and Departments of Radiation Oncology (B.G.W.) and Medical Biophysics (B.G.W.), University of Toronto, Toronto, Ontario, Canada f.hunter@auckland.ac.nz.
Abstract:
Evofosfamide (TH-302) is a hypoxia-activated DNA-crosslinking prodrug currently in clinical development for cancer therapy. Oxygen-sensitive activation of evofosfamide depends on one-electron reduction, yet the reductases that catalyze this process in tumors are unknown. We used RNA sequencing, whole-genome CRISPR knockout, and reductase-focused short hairpin RNA screens to interrogate modifiers of evofosfamide activation in cancer cell lines. Involvement of mitochondrial electron transport in the activation of evofosfamide and the related nitroaromatic compounds EF5 and FSL-61 was investigated using 143B ρ 0 (ρ zero) cells devoid of mitochondrial DNA and biochemical assays in UT-SCC-74B cells. The potency of evofosfamide in 30 genetically diverse cancer cell lines correlated with the expression of genes involved in mitochondrial electron transfer. A whole-genome CRISPR screen in KBM-7 cells identified the DNA damage-response factors SLX4IP, C10orf90 (FATS), and SLFN11, in addition to the key regulator of mitochondrial function, YME1L1, and several complex I constituents as modifiers of evofosfamide sensitivity. A reductase-focused shRNA screen in UT-SCC-74B cells similarly identified mitochondrial respiratory chain factors. Surprisingly, 143B ρ 0 cells showed enhanced evofosfamide activation and sensitivity but had global transcriptional changes, including increased expression of nonmitochondrial flavoreductases. In UT-SCC-74B cells, evofosfamide oxidized cytochromes a, b, and c and inhibited respiration at complexes I, II, and IV without quenching reactive oxygen species production. Our results suggest that the mitochondrial electron transport chain contributes to evofosfamide activation and that predicting evofosfamide sensitivity in patients by measuring the expression of canonical bioreductive enzymes such as cytochrome P450 oxidoreductase is likely to be futile.
Insights
Evofosfamide activation in cancer relies on mitochondrial electron transport, not just traditional reductases. This finding impacts how we predict patient response to this hypoxia-activated prodrug.
Area of Science:
- Molecular Biology
- Cancer Therapeutics
- Cellular Respiration
Background:
- Evofosfamide (TH-302) is a hypoxia-activated prodrug for cancer therapy.
- Its activation requires one-electron reduction, but tumor reductases remain unidentified.
Purpose of the Study:
- To identify the reductases responsible for evofosfamide activation in tumors.
- To investigate the role of mitochondrial electron transport in evofosfamide's mechanism of action.
Main Methods:
- RNA sequencing, CRISPR knockout, and shRNA screens were used to identify modifiers of evofosfamide activation.
- Experiments utilized cancer cell lines, including mitochondrial DNA-deficient cells (143B ρ0) and biochemical assays.
Main Results:
- Evofosfamide potency correlated with mitochondrial electron transfer gene expression.
- CRISPR and shRNA screens identified mitochondrial factors (e.g., YME1L1, Complex I) and DNA damage factors (SLX4IP, FATS, SLFN11) as modifiers.
- Mitochondrial DNA-deficient cells showed enhanced activation, suggesting non-canonical pathways.
Conclusions:
- The mitochondrial electron transport chain significantly contributes to evofosfamide activation.
- Predicting evofosfamide sensitivity based on canonical bioreductive enzymes like cytochrome P450 oxidoreductase may be unreliable.
Related Concept Videos
Electron Transport Chains
The ETC is comprised of...
Secondary Active Transport
Primary Active Transport
Protein Transport into the Inner Mitochondrial Membrane
Transport of mitochondrial precursors across the TIM23 channel is driven by...
The Electron Transport Chain
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
Active Transport
Primary active transporters, like Na+, K+ and -ATPase, directly utilize ATP to move ions across the membrane. These transporters play significant roles in various physiological processes. For instance, Na+, K+ and -ATPase maintain...

